KYMR
Kymera Therapeutics Inc
115.80$
+0.3%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +912.8% | -78.5% | +149.3% | -85.4% | +97.6% | +198.9% | -48.1% | -75.9% | +3.5% | +1,101.6% | +89.1% | – | |
| – | -3.9% | +73.4% | +26.7% | +5.3% | -1.3% | +3.8% | +1.8% | +3,455.4% | -202.8% | – | – | – | |
| – | +912.8% | -78.5% | +149.3% | -85.4% | +97.6% | +198.9% | -57.5% | -859.5% | – | -56.5% | +89.1% | – | |
| – | +10.1% | -7.8% | +21.3% | +2.0% | +18.9% | +11.7% | -2.3% | -5.5% | +13.2% | +17.1% | +21.7% | – | |
| – | +0.8% | +1.0% | +20.9% | -11.0% | +5.7% | -0.4% | +8.4% | -1.8% | -2.2% | +20.1% | +3.8% | – | |
| – | +8.0% | +1.4% | +12.4% | -0.9% | +16.2% | +9.5% | -2.7% | -77.4% | +734.9% | -33.0% | +18.6% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +26.8% | +32.7% | -11.6% | -1.6% | -1.7% | +22.0% | +50.0% | -9.3% | -29.6% | -11.6% | +32.8% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | -99.2% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.